Revolution Medicines has dosed the first patient in RMC-5127-001 (NCT07349537), a first-in-human, open-label study of RMC-5127, a selective inhibitor of the active, GTP-bound RAS G12V variant. The trial will assess safety, tolerability, pharmacokinetics, and early antitumor activity as monotherapy and in combination cohorts across patients with RAS G12V–mutated pancreatic ductal adenocarcinoma, colorectal cancer, and non–small cell lung cancer who have exhausted or cannot tolerate standard options, including prior targeted therapies. RMC-5127 employs Revolution’s tri-complex approach, binding cyclophilin A to recognize and inhibit RAS(ON) G12V. G12V is the second most common RAS oncogenic variant, with an estimated tens of thousands of new cases annually in the U.S., concentrated in PDAC, CRC, and NSCLC.
The move extends the company’s variant-by-variant RAS(ON) franchise. With daraxonrasib (multi-selective), elironrasib (G12C-selective), and zoldonrasib (G12D-selective) already in the clinic, RMC-5127 adds coverage of a prevalent mutation with no approved targeted treatments. Structurally, the study’s design signals intent to map a development path quickly: start with monotherapy signal-finding and tolerability, then layer combinations to counter adaptive signaling—an approach that has proven necessary in KRAS-mutant CRC and is increasingly standard across RAS-driven tumors. Given the company’s internal portfolio, rational doublets that stay within the RAS pathway are likely the near-term focus, reducing dependency on external partnerships while keeping timelines under company control.
Operationally, sites should expect a classic biomarker-driven basket trial with high screening friction. Confirming G12V status will hinge on broad NGS access and fast turnaround, and sites serving PDAC and refractory CRC populations will confront performance status deterioration and screen failure rates that can erode enrollment velocity. Sponsors and CROs will need to optimize pre-screening pipelines, incorporate ctDNA-based eligibility to reduce repeat biopsies where possible, and centralize variant verification to standardize cohort assignment. Combination cohorts introduce additional scheduling and safety monitoring complexity in a population predisposed to hepatic and GI toxicities; careful DLT management and early pharmacodynamic readouts will be critical to keep dose escalation on track. Drug product logistics also matter: a tri-complex modality may present formulation nuances that affect dose proportionality and food effects, which in turn can complicate site workflows and patient adherence in later expansion.
Regulatoryly, the study sits at the intersection of mutation-specific and tumor-agnostic strategies. While mutation-specific precedents exist in G12C NSCLC, heterogeneity across histologies has repeatedly forced indication-by-indication development. For G12V, the commercial and regulatory leverage will likely come from the first setting that delivers a clean, reproducible signal with manageable toxicity. NSCLC could offer a clearer efficacy bar, but CRC may necessitate combinations to overcome feedback loops, and PDAC remains the toughest readout for single-agent activity. Any early evidence of consistent ctDNA declines across tumor types would support broader expansion and set up parallel dialogues with FDA and ex-U.S. agencies.
What to watch next: tolerability at pharmacologically active exposures, depth and durability of early responses, and biomarker evidence of pathway suppression that supports combination hypotheses. If safety is favorable, rapid expansion into histology-specific cohorts and internally controlled doublets is the logical next step. Risks include enrollment drag tied to biomarker logistics, the operational burden of multi-arm combinations, and portfolio complexity that can strain manufacturing and trial resourcing. For stakeholders across sites and CROs, the signal to noise in PDAC and CRC will determine whether this program accelerates or pauses for regimen refinement.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
